Research studies suggest that blocking IDO2 could improve immune response by reducing tumor-induced immune suppression, however, clinical trials focused on IDO2 are still in the early stages, and their efficacy remains under investigation [11,12]. The gene discussed is IDO2; the disease is neoplasm.